The practical choice a cartilage diagnosis puts in front of you

A confirmed focal cartilage defect in the knee — an isolated, full-thickness lesion that catches on movement and limits activity — sits in a specific clinical category: one where repair is genuinely on the table. Unlike diffuse osteoarthritis, a focal defect has defined edges, healthy surrounding cartilage, and no widespread bone involvement. That combination makes it amenable to restoration rather than simply management.

Three meaningfully different pathways address it. ChondroFiller injection is an outpatient, ultrasound-guided procedure that places an acellular collagen scaffold directly into the defect — no operating theatre, no general anaesthetic, no surgical incision. OATS transfers osteochondral cylindrical plugs from a non-weight-bearing zone of the same knee in a single arthroscopic operation. MACI requires two separate procedures: an arthroscopic cell harvest, a laboratory culture period of several weeks, then a second operation to implant those cells on a collagen membrane — the most surgically intensive of the three.

Deciding between them turns on four variables: the size and depth of the defect, whether the patient is a suitable surgical candidate, how much rehabilitation they can realistically sustain, and cost tolerance. No randomised controlled trial has directly compared all three; each treatment carries its own independent evidence base, and any comparison drawn here is indirect.

What each treatment actually involves

The procedural differences run deeper than simply injection versus surgery — they reflect fundamentally different theories of repair.

ChondroFiller injection works through matrix-induced chondrogenesis: the injectable Type I collagen hydrogel gels in situ inside the defect cavity, creating a three-dimensional scaffold that draws the patient's own progenitor cells into the site and supports their differentiation into repair tissue. Preparation is minimal — the defect is located by ultrasound and the scaffold placed under image guidance in a single outpatient visit. No tissue is removed, and the surrounding joint structures are left intact.

OATS begins with the surgeon identifying a donor site in a low-load zone of the same knee — typically the peripheral femoral condyle — from which cylindrical osteochondral plugs are harvested under regional or general anaesthetic and press-fitted directly into the defect. Bone-to-bone contact drives structural integration; no laboratory processing period is required. The defect bed must be debrided to a clean base before the plugs are seated.

MACI divides the procedure into two theatre visits separated by four to six weeks of laboratory work. The first is a short arthroscopic biopsy: a small cartilage sample is sent to the laboratory, where the patient's own chondrocytes are isolated, expanded, and seeded onto a Type I/III collagen membrane. The second operation implants that cell-laden membrane into the prepared defect site.

Both OATS and MACI require arthroscopic debridement to a dry, stable base before anything is placed — a step that commits the surgeon to removing tissue. ChondroFiller injection involves no such preparation and adds to what is already there rather than first taking tissue away.

Defect size and who each option is best suited for

Defect size is the starting point for every treatment discussion, but it is rarely the only factor — and in one important size range, it is not even the deciding one.

ChondroFiller injection is indicated for focal ICRS Grade III or IV lesions with healthy surrounding cartilage borders. The primary evidence base covers defects up to 3 cm², with clinical evaluation data documenting use up to 6 cm². It is particularly well suited to patients for whom surgery is disproportionate — those with relative contraindications to general anaesthetic, limited capacity for post-operative rehabilitation, or defects in otherwise stable joints where removing tissue would add risk without adding clear benefit.

OATS is the single-stage surgical standard for smaller defects, typically under 2 cm², where one or two plugs provide clean coverage. Mosaicplasty — multiple plugs — extends this to roughly 4 cm², but the gaps between plugs do not fill with hyaline cartilage; they heal with inferior fibrocartilage. Harvest from the low-load donor zone carries genuine trade-offs: residual donor-site discomfort and local structural change are real considerations, not theoretical ones.

MACI is justified for larger isolated lesions. Its collagen membrane can be trimmed to cover defects up to approximately 20 cm², and the SUMMIT trial supports its use for lesions ≥3 cm² in patients aged 18–55. It performs poorly in older patients and is unsuitable where joint-surface changes extend beyond a defined focal area.

The 2–4 cm² range is a genuine grey zone. Published evidence from Richter et al. (2015) shows OATS and MACI produce clinically equivalent outcomes in this window — meaning defect size stops being the discriminating factor and the patient's capacity to manage surgical recovery becomes the deciding question instead.

All three options share one prerequisite: a mechanically stable joint. Significant ligament laxity, uncorrected axial malalignment, or advanced degenerative change in adjacent compartments should be addressed before cartilage repair is attempted, or may indicate that the patient sits outside the repair pathway entirely.

What the outcomes evidence shows

Clinical evidence for all three options deserves a clear-eyed reading — particularly on evidence quality, not just headline numbers.

ChondroFiller injection

Across four published clinical studies, ChondroFiller injection produces a consistent improvement of approximately 30 points on the IKDC scale — from a baseline of around 48, indicating significant activity limitation, to approximately 78–80 at three years. The bulk of that functional gain consolidates within the first twelve months. More than 80% of treated patients report satisfaction with their results, and MOCART MRI scores — reflecting the quality of scaffold integration and repair tissue on imaging — average between 70 and 87. At three to five years, 70–85% of patients achieve meaningful symptom relief. These are prospective cohort studies and multi-centre trials, not large phase III randomised controlled trials; the numbers are encouraging but should be read with that in mind.

OATS

For appropriately sized defects, OATS has robust long-term structural data. Gudas et al. (2012) reported durable outcomes at ten years compared with microfracture in a well-matched cohort — one of the more convincing durability datasets in this field. Beyond approximately 4 cm², however, the limitations described in the earlier section translate into measurable outcome decline: inter-plug fibrocartilage fill rather than hyaline repair tissue, and accumulating donor-site morbidity.

MACI

In carefully selected patients aged 18–55 with isolated focal damage, MACI shows success rates of 75–90%. The SUMMIT trial is the best-quality reference point: it demonstrated improved KOOS pain and function scores at both two and five years for defects of 3 cm² or larger when MACI was compared with microfracture.

The central evidence gap

No head-to-head randomised trial has directly compared ChondroFiller injection with either MACI or OATS. Every cross-option comparison in this article — and in the published literature — is indirect. That is not a reason to avoid treatment decisions, but it is the honest frame within which all the numbers above should be interpreted.

Cost and recovery burden side by side

Putting the numbers alongside each other makes the scale of the differences concrete.

ChondroFiller injection is priced from approximately £3,000 in the UK private sector. The procedure is outpatient and ultrasound-guided, requiring no general anaesthetic and no inpatient stay. Post-procedure recovery involves six weeks of protected partial weight-bearing; most patients return to normal daily activity without a formal rehabilitation programme of the kind surgical options require. Of the three pathways, this carries the lowest overall burden of time and disruption.

OATS is priced at approximately £14,000 at London Cartilage Clinic — roughly five times the cost of ChondroFiller injection, and around half that of two-stage MACI. As a single procedure with bone-to-bone healing, it offers faster structural stability than the cell-based pathway. Return to sport typically falls in the 4–6 month range.

MACI costs £25,000–£35,000 or more in the UK private sector, reflecting two separate surgical procedures plus laboratory cell-culture costs. Return to jogging is expected at 7–9 months; distance running at 9–12 months or beyond. It carries the longest recovery burden of the three options. Niemeyer (2019) noted that annual costs in years four and five post-surgery were lower than in comparison groups — suggesting the total cost picture may improve over a longer horizon, though the upfront commitment remains substantially higher.

Insurance coverage for ChondroFiller injection has been reported with Bupa, Aviva, and WPA under CCSD codes W3111 and W8500, but approval is not automatic — each case requires individual pre-authorisation, and patients should obtain written confirmation before proceeding. MACI and OATS carry broader insurer recognition as established surgical procedures, though reimbursement thresholds are correspondingly higher.

When comparing costs, the procedure fee is only part of the picture. Physiotherapy, time away from work, and the possibility of re-intervention are all relevant inputs — particularly for MACI, where the two-stage process extends the overall commitment considerably.

Getting the right assessment for your defect

The decision between ChondroFiller injection, OATS, and MACI turns on four intersecting variables: confirmed defect size on MRI or arthroscopy, patient age and activity level, surgical candidacy, and — critically — rehabilitation capacity. No single option is best across all presentations, and outcome percentages alone cannot resolve that question.

For a focal defect where a commitment to surgical rehabilitation is not feasible, ChondroFiller injection remains genuinely competitive across a wide size range. OATS is the established single-stage surgical standard where the defect is small and bone-to-bone healing is the priority. MACI is best reserved for larger, isolated lesions in younger patients who can accept the two-stage pathway and its extended recovery burden.

What the evidence does not support is a one-size-fits-all approach, or a decision made without imaging-confirmed defect sizing and a thorough review of activity goals. An experienced cartilage specialist will bring those variables together before settling on a pathway — defect grade, lesion dimensions, joint health, lifestyle, and surgical suitability all inform the final recommendation. Patients should be wary of any route that bypasses that assessment, whatever the technique being offered.

For those weighing their options, an initial specialist consultation is the practical next step — and the right place to map a specific lesion to the most appropriate pathway.